Overview of the Treatment of Myelofibrosis

Opinion
Video

A hematologist-oncologist gives an overview of the treatment of myelofibrosis by defining the disease and highlighting biological pathways, therapeutic options, and factors that drive treatment selection.

Case: A 62-Year-Old Man with Myelofibrosis

Clinical Presentation:

  • A 62-year-old man presented with symptoms of fatigue, night sweats, and increased bruising.
  • PMH: type 2 diabetes, hypercholesteremia, and hypertension
  • 1 year prior, patient had a “normal” physical and blood work.
    • PCP noticed lower Hg (11 to 9.5 g/dL) and Plt (350 to 195 cells/m3)
  • Patient was referred to Hem/Onc – first available appoint in 2 months.

Initial Clinical Workup and Diagnosis (Post-PCP Visit):

  • Exam: fatigue and night sweats worsening; bone pain.
  • Labs: RBC 3.40 x 1012/L; Hb 8.7 g/dL; Hct 36%; MCV 94fL; WBC 28.0 x 109/L; Plt 75 x 109/; LDH 330 IU/L
  • Spleen: 5 cm below LCM
  • Bone Marrow Fibrosis: Grade 2
  • Bone Marrow Blasts: 3%
  • Blood Smear: leukoerythroblastosis; 1% blasts by manual count/flow cytometry
  • Molecular Analysis: JAK V617F+
  • ECOG PS 2
  • Diagnosis: Primary MF

Current Treatments:

  • Patient was initiated on pacritinib.
Related Videos
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Prithviraj Bose, MD, an expert on myelofibrosis
Prithviraj Bose, MD, an expert on myelofibrosis
Related Content
Gene Variant Raises ALL Risk in Hispanic/Latino Children

Gene Variant Raises ALL Risk in Hispanic/Latino Children

April 6th 2024
Article

Adam de Smith, PhD, discussed findings from a study investigating a genetic variant that increases the risk of acute lymphoblastic leukemia in Hispanic/Latino pediatric patients. 

Read More

Examining Efficacy, Toxicity, and Cost-Effectiveness of Myeloma Therapies

Examining Efficacy, Toxicity, and Cost-Effectiveness of Myeloma Therapies

April 1st 2024
Article

In an interview with Targeted Oncology, Doris Hansen, MD, delved into the background, methods, design, and results from 3 recent myeloma studies.

Read More

Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers

Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers

March 21st 2024
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.

Read More

Addressing MDS Treatment Gap Post Hypomethylating Failure

Addressing MDS Treatment Gap Post Hypomethylating Failure

March 21st 2024
Article

The frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.

Read More

FDA Lifts Clinical Hold on Trial of NX-2127 in B-Cell Malignancies

FDA Lifts Clinical Hold on Trial of NX-2127 in B-Cell Malignancies

March 11th 2024
Article

Following changes to the manufacturing process, the phase 1 study of NX-2127 in B-cell malignancies has been cleared to continue by the FDA.

Read More

GemCloBu: A New Conditioning Regimen for Aggressive Lymphomas

GemCloBu: A New Conditioning Regimen for Aggressive Lymphomas

March 9th 2024
Article

Jeremy Ramdial, MD, discussed a phase 1/2 study investigating the GemCloBu conditioning regimen for stem cell transplants in aggressive lymphomas.

Read More